SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Fresenius in license agreement with Sanofi-Aventis

06 Apr 2010 Evaluate

Fresenius Kabi Oncology Ltd has entered into a license and settlement agreement with Sanofi-Aventis for injectable drug Eloxatin. The agreement resolves a patent infringement suit filed by Sanofi-Aventis in June 2007 in the US. Eloxatin is used for the treatment of stage-III colon cancer. The drug had net sales of $993 million in the US market in year 2009.

crackcrack
Peers
Company Name CMP
Sun Pharma Inds. 1686.70
Dr. Reddys Lab 1215.55
Cipla 1228.40
Zydus Lifesciences 937.95
Lupin 2323.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×